Charles Piller

And the logic of this is that the companies need the approval, and consequently, they should subsidize the agency to do this examination. But in my opinion, and I think in the opinion of a lot of people who have studied this, this creates an inherent conflict of interest for the agency.

And the logic of this is that the companies need the approval, and consequently, they should subsidize the agency to do this examination. But in my opinion, and I think in the opinion of a lot of people who have studied this, this creates an inherent conflict of interest for the agency.

The people who are essentially paying for their salaries are the ones who they are really wanting them to sign off on a particular drug.

The people who are essentially paying for their salaries are the ones who they are really wanting them to sign off on a particular drug.

The people who are essentially paying for their salaries are the ones who they are really wanting them to sign off on a particular drug.

There's also the phenomenon that they call the revolving door, where people who are involved in the drug approval process in the federal government leave the agency, go to work for the drug companies that they were earlier passing judgment over, and now they're on the other side of it, earning four times their earlier salary. So that can be a powerful incentive as well.

There's also the phenomenon that they call the revolving door, where people who are involved in the drug approval process in the federal government leave the agency, go to work for the drug companies that they were earlier passing judgment over, and now they're on the other side of it, earning four times their earlier salary. So that can be a powerful incentive as well.

There's also the phenomenon that they call the revolving door, where people who are involved in the drug approval process in the federal government leave the agency, go to work for the drug companies that they were earlier passing judgment over, and now they're on the other side of it, earning four times their earlier salary. So that can be a powerful incentive as well.

What I think that the federal government should do is fund those drug evaluations from tax dollars because it's a much cleaner way that removes some of the conflicts of interest. And I know that they can't pay every FDA official the amount they could make at a drug company, but, um, at least starting with, uh,

What I think that the federal government should do is fund those drug evaluations from tax dollars because it's a much cleaner way that removes some of the conflicts of interest. And I know that they can't pay every FDA official the amount they could make at a drug company, but, um, at least starting with, uh,

What I think that the federal government should do is fund those drug evaluations from tax dollars because it's a much cleaner way that removes some of the conflicts of interest. And I know that they can't pay every FDA official the amount they could make at a drug company, but, um, at least starting with, uh,

being able to control that process fully and not depend on corporate fees, I think would be a good step.

being able to control that process fully and not depend on corporate fees, I think would be a good step.

being able to control that process fully and not depend on corporate fees, I think would be a good step.

For sure. Why, United States, we have the highest cost, the most money spent on healthcare, yet we don't have the greatest outcomes. Why do you think that's the case? Well, I mean, I think- Loaded question, right? That is a big question.

For sure. Why, United States, we have the highest cost, the most money spent on healthcare, yet we don't have the greatest outcomes. Why do you think that's the case? Well, I mean, I think- Loaded question, right? That is a big question.

For sure. Why, United States, we have the highest cost, the most money spent on healthcare, yet we don't have the greatest outcomes. Why do you think that's the case? Well, I mean, I think- Loaded question, right? That is a big question.

Only on a podcast we can ask that because normally on a TV segment, you'll have three minutes. It's like, go.

Only on a podcast we can ask that because normally on a TV segment, you'll have three minutes. It's like, go.

Only on a podcast we can ask that because normally on a TV segment, you'll have three minutes. It's like, go.